A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysis

Juan Gaztañaga, Stuart D. Katz, Ann Marie Schmidt et al.|Diabetes & Metabolic Syndrome Clinical Research & Reviews|2021

Cited by 14